Press releasePRNewswire
American Century ETF Trust
ACEM · NASDAQ · ETF
$38.47+$0.7639 (+2.03%)TodayMarket closed ·
No price history for this range.
ACEM key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 409
- Volume
- 100.61K
- Open price
- $38.63
- High today
- $38.63
- Low today
- $38.47
- 52 Week high
- $38.49
- 52 Week low
- $37.71
American Century ETF Trust (ACEM) at a glance
As of Nov 6, 2026, American Century ETF Trust (ACEM) shares are priced at $38.47, giving the company a price-to-earnings ratio of 0.00.
Today the fund has traded between $38.47 and $38.63. The current price is 0.0% above the day's low and 0.4% below its high.
Volume so far is 100.61K shares, above the average of 409 shares a day.
Over the past year American Century ETF Trust has ranged from $37.71 to $38.49, and now sits 97% of the way up that range.
ACEM news
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003+0.00%
- RCTRedCloud Holdings$0.0424+41.33%
- SHFSSHF Holdings$0.0263−1.13%
- SDASunCar Technology Group$0.3765+144.80%
- WDLFDecentral Life$0.0004+100.00%
- SEIISharing Economy International$0.0001−50.00%
- SOXLDirexion Shares ETF Trust$45.97+12.48%
- VIVKVivakor$0.4962+34.11%
- MASNMaison Luxe$0.0003−33.33%
- NBNDNetBrands$0.0005+11.11%
- NVDANVIDIA$186.64+2.78%
- INTCIntel$56.28+7.71%
Newly listed
Companies that went public in the past six weeks
- NARANarragansett Bancorp$10.84−0.28%
- ASPEAspen Neuroscience$12.44+5.78%
- BBTXBambusa Therapeutics$15.73−0.76%
- GBCGEORGIA BANKING$33.10−1.93%
- BHAIUBHAV Acquisition Corp II$9.99+0.00%
- SCQCUSPACCircle Acquisition$10.00+0.10%
- LYCALycia Therapeutics$30.50+5.90%
- DAVIDAVION HEALTHCARE$1.59+21.37%
- TCXBTCGX Acquisition Corp. II$10.20−0.49%
- CTYCITY THERAPEUTICS$18.25+6.91%
- IAMIambic Therapeutics$10.17−12.63%
- AMROAmaero$5.45+1.87%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.